[{"address1": "42127 Pleasant Forest Court", "city": "Ashburn", "state": "VA", "zip": "20148-7349", "country": "United States", "phone": "703 980 4182", "website": "https://quoinpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael  Myers Ph.D.", "age": 61, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 962925, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Denise  Carter", "age": 54, "title": "Co-Founder, COO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 778700, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gordon Bruce Dunn J.D.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 591300, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.7471, "open": 0.74, "dayLow": 0.7215, "dayHigh": 0.7945, "regularMarketPreviousClose": 0.7471, "regularMarketOpen": 0.74, "regularMarketDayLow": 0.7215, "regularMarketDayHigh": 0.7945, "beta": 2.029, "forwardPE": -0.6267769, "volume": 121360, "regularMarketVolume": 121360, "averageVolume": 2605225, "averageVolume10days": 800220, "averageDailyVolume10Day": 800220, "bid": 0.7055, "ask": 0.7929, "bidSize": 800, "askSize": 800, "marketCap": 3829707, "fiftyTwoWeekLow": 0.477, "fiftyTwoWeekHigh": 6.18, "fiftyDayAverage": 0.64238, "twoHundredDayAverage": 1.09007, "currency": "USD", "enterpriseValue": -6328447, "floatShares": 3882580, "sharesOutstanding": 5049720, "sharesShort": 19172, "sharesShortPriorMonth": 193530, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0047999998, "heldPercentInsiders": 0.02447, "heldPercentInstitutions": 0.06093, "shortRatio": 0.2, "shortPercentOfFloat": 0.0047999998, "bookValue": 1.879, "priceToBook": 0.40361896, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -8277870, "trailingEps": -5.05, "forwardEps": -1.21, "enterpriseToEbitda": 0.716, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "QNRX", "underlyingSymbol": "QNRX", "shortName": "Quoin Pharmaceuticals, Ltd.", "longName": "Quoin Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1470058200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "32cb2815-c927-3d74-8136-d444e5765139", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.7584, "targetHighPrice": 10.0, "targetLowPrice": 2.0, "targetMeanPrice": 4.67, "targetMedianPrice": 2.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 12570589, "totalCashPerShare": 3.158, "ebitda": -8836608, "totalDebt": 3223733, "quickRatio": 3.18, "currentRatio": 3.345, "debtToEquity": 43.108, "returnOnAssets": -0.36318, "returnOnEquity": -1.00033, "freeCashflow": -5049371, "operatingCashflow": -7986664, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-04"}]